In vivo studies were conducted to compare the activity of three non-steroidal anti-inflammatory drugs as inhibitors of urinary bladder carcinogenesis induced in B6D2F, (BDF) mice by A f -butyl-A^-(4-hydroxybutyl)nitrosamine (OH-BBN). Mice received continuous dietary exposure to nontoxic doses of aspirin, sulindac or ketoprofen beginning 1 week prior to the first of eight weekly doses of 7.5 mg OH-BBN; studies were terminated at 24 weeks after the first carcinogen dose. Both dose levels of sulindac (200 and 400 mg/kg diet) and both dose levels of ketoprofen (40 and 80 mg/kg diet) reduced the incidence of transitional cell carcinoma of the urinary bladder by >70% from that seen in dietary controls. The high dose of sulindac conferred the greatest protection against bladder cancer induction. In contrast, when administered at 400 and 800 mg/kg diet aspirin was inactive as a chemopreventive agent in the OH-BBN/BDF bladder cancer model. The significant potency of sulindac and ketoprofen as inhibitors of urinary bladder carcinogenesis, when considered with their history of safe human use, suggests that these agents merit further study as drugs for cancer chemoprevention in this target tissue.
Introduction
Eicosanoid biosynthethic pathways have been demonstrated to be appropriate targets for cancer chemoprevention in a wide range of target tissues in experimental animals. Cancer induction may be inhibited by suppressing the production of arachidonic acid via administration of drugs that inhibit the activity of phospholipases (1) or by specific or non-specific inhibition of several enzymatic pathways of arachidonic acid catabolism (2) (3) (4) . Because the levels of prostaglandins and the activity of prostaglandin endoperoxide synthase (cyclooxygenase; COX*) are both elevated in tumor cells (5, 6) , suppression of COX activity through the administration of non-steroidal antiinflammatory drugs (NSADDs) presents a viable mechanistic approach to cancer prevention. The rationale for the use of NSAIDs for cancer chemoprevention is further strengthened by the long history of human use of these agents, resulting in the development of extensive toxicological profiles for many
•Abbreviations: COX, cyclooxygenase, prostaglandin endoperoxide synthase; NSAIDs, non-steroidal anti-inflammatory drugs; TCC, transitional cell carcinomas; OH-BBN, N-butyl-A'-(4-hydroxy)nitrosamine; MTD, maximum tolerated dose. members of this drug class (7) . Although significant toxicity is associated with high doses of these drugs, many years of clinical experience have resulted in the identification of dose levels of several NSAIDs that can be administered chronically to humans without adverse side effects.
Studies from a number of laboratories, including our own, have demonstrated that several commonly prescribed NSAIDs (aspirin, indomethacin and piroxicam) can suppress cancer induction in various sites in experimental animals (reviewed in 8). Effective chemoprevention by NSAIDS has been demonstrated in experimental models for cancer of the breast (9-11), colon (12,13), urinary bladder (14) (15) (16) (17) , esophagus (18) and skin (2) , among other tissues. Recent studies in clinical populations have also demonstrated anti-tumor activity for this class of compounds: aspirin has significant chemopreventive activity in the colon, as its use is associated with reduced incidence of both colonic adenomas and invasive cancers (19, 20) , while regression of colonic and rectal adenomas has been reported in patients treated with sulindac (21) .
Although limited in scope, the available clinical data for colon cancer prevention provide strong support for the study of NSAIDs as cancer chemopreventive agents in other organ systems. The urinary bladder is a target tissue in which NSAIDs might reasonably be expected to have useful chemopreventive activity in humans (22) . The present studies were conducted to generate comparative data for the anti-carcinogenic activity of several NSAIDs, in order to identify one or more agents that merit consideration for use in clinical trials for the prevention of urinary bladder cancer.
Materials and methods

Animals and animal husbandry
Male C57BI/6XDBA/2-FJ (BDF) mice were obtained at 5-6 weeks of age from colonies maintained at the National Cancer Institute-Frederick Cancer Research Facility (Frederick, MD). Mice were housed in groups of five on hardwood bedding in polycarbonate cages in windowless animal rooms. Animal rooms were illuminated on a 12 h light/dark cycle and were maintained at a temperature of 22 ± 1°C and a relative humidity of 50 ± 20%. Mice were permitted free access to modified AIN-76A semi-purified diet (Teklad Test Diets, Madison, WI) and drinking water at all times during the study. After a minimum quarantine period of 1 week, animals were randomized into treatment groups using a constrained randomization procedure that blocks for body weights. Administration of test diets supplemented with chemopreventive agents was begun at this time and was continued through to the end of each study. Throughout the studies animals were observed twice daily to assess their general health status and were weighed weekly.
Chemopreventivc agents
Aspirin and ketoprofen were purchased from Sigma Chemical Co. (St Louis, MO) and sulindac was obtained from the chemoprcventive agent repository maintained by the Division of Cancer Prevention and Control (National Cancer Institute, Frederick, MD). The purity of all chemopreventive agents and the stability and homogeneity of each agent in test diets were determined prior to use in carcinogenesis studies. Dietary concentrations of chemopreventive drugs were verified by HPLC analysis of diet samples obtained at regular intervals throughout the studies.
Induction of urothelial carcinomas
Transitional cell carcinomas (TCC) of the urinary bladder were induced in BDF mice by weekly oral (gavage) administration of /S'-butyl-/V-(4- Pnoi lo the inilialion ot iheinopievculion studies the m.i\inii]iii lolciated dose (MTD) loi each NSA1D vsas deleiiDined in a preliminary subchronic elose selection/diet tolerance slud\ I'he V1TI) was dehned as the highest dieUin level ol each agent that could be administered In BDF mice lor a minimum period ot d weeks without the induction ot gross or systemic IOMCII) or the suppiession ol bod\ wemhl njin ()n ihe basis ol these preliminary studies, the lollouing MTIK were dehned aspirin 1IKM) mg/kg diet, keloproten. KM) mg/kg diet, suhnd.ic. 5(M) mg/kg diet Because ol Immalions m ammal a\ ailahdilv (wo ^heinoprevenlioii sludies were conducted The anti-c.ircinogenic activities ol aspirin anil keloproten were assessed in a single study, while sulindac was evaluated in a second study In Ihe ehemoprevenlion studies all NSAIDs were administered as dietary supplements at doses ot OS and 0 4 VITl). ehemopreventive agent administration was initiated 1 week prior lo the lirsi dose ol OH-BBN and was continued uninlernjpted until the termination ot the studies at 24 weeks A group si/e ot 75 animals was used to provide adequate statistical power, the expected TC'C incidence at 24 weeks post-carcinogen was -30'( in dietary controls Two studies were conducted to evaluate the anti-carcinogenic activity ol NSAIDs in the mouse urinary bladdei Aspirin and ketoproten were evaluated tor elticacv in Study I. while suhnd.ic was tested toi ehemopreventive activity in Study 2 /Vet ropw iintl lu\lopiillii>loi;\ Animals tound dead during the studv were neeropsied immediately upon discovery, and moribund animals were neeropsied immediately alter being killed b\ CO; asphyxiation Suniv ing animals were killed by COi asphyxiation at 24 weeks alter the hrst carcinogen dose Al necropsy the bladder Iron) each animal was inllated in \itu with K)*' 1 neutral bullered tomialin The bladder was then excised and Iransilluminated to identity gross abnormalities, such as vasculari/alion or opacities Hach aiea ol abnormality was mapped and Ihe bladdei map served as a guide lo histological operations If no abnormalities were noted by the prosector the bladder was bisected and examined lor gross lesions Each bladder halt was then bisected ami gloss lesions and random areas ol phenolypically normal bladder were excised and embedded ill par.illin Replicate sections Irom each block weie cut at 5 Jim and stained with hematoxyhn and eosm toi microscopic evaluation. TC'C were classified using previously published diagnostic criteria |24| To eliminate bias by Ihe palhologist. slides were evaluated without the accompanying necropsy sheet The type ol lesion location ami depth ol invasion were noted, in order to quantity tumor incidence and to determine it a shilt lo a less invasive lesion may have occurred as a result ol chemopievenlive agent administiation
SkiliMn til tunih MS
Intergroup dilleiences in the incidence ot ICC were compared using I'isher s exact tesl (X'easional losses ot tissues due lo cannibalism or aulolysis were responsible lor instances where bladders from <-75 carcinogen-treated animals/ group were evaluated histopathologically Comparisons ol group mean body wemhts were pcriormed using analysis ol variance and mtergroup dillerences in suivival were compared using ihe log rank lest
Results
Dietary administration of non-toxic doses of sulindac and ketoprofen. but not aspirin, resulted in statistically significant reductions in the incidence of TCC in BDF mice treated with OH-BBN. In Study 1 the incidence of TCC in the dietary control group was 22/75, or 29% (Table I) : this incidence of urinary bladder cancer is consistent with that seen in other studies conducted in our laboratory using the 0H-BBN/BDF mouse model system. In comparison with the 297c incidence of TCC seen in dietary controls, groups receiving dietary supplementation with ketoprofen at the 80 and 40 mg/kg diet dose levels demonstrated bladder cancer incidences of 6 and 1% respectively (P < 0.01 versus control for both ketoprofen groups). In contrast to the significant anti-carcinogenic activity of ketoprofen, dietary administration of aspirin conferred no protection against bladder cancer induction. TCC incidence was 30 and 28% in the groups fed aspirin at 800 and 400 mg/kg diet respectively; these incidences of TCC are essentially identical to that seen in the dietary control group.
The activity of the high dose of sulindac as a chemopreventive agent for urinary bladder cancer was greater than that of any agent evaluated in our laboratory over the past 15 years. As seen in Table II , dietary administration of sulindac resulted in a dose-related suppression of bladder cancer induction by OH-BBN: TCC incidence was reduced from 27% (20/74) in the dietary control group to 3 (2/75) and 8% (6/73) by the 400 and 200 mg/kg diet dose levels of sulindac respectively (P < 0.01 versus control for both sulindac groups). " Diagnosed lesions demonstrated the expected histological pattern of TCC with varying degrees of glandular and/or squamous differentiation. There were no significant differences in lesion histopathology, severity or invasiveness in animals from different groups that developed bladder cancer. Tumor responses in the dietary control groups in the two studies were very similar (29 and 27%), demonstrating the reproducibility of the model system. Levels of chemopreventive agents used in the studies were essentially non-toxic. No overt toxicity was identified in any animal in either study and terminal survival was >90% in all experimental groups in both studies. Neither aspirin nor ketoprofen had any effect on group mean body weight at any time in the study, however, small (4.5 and 6.0%) but statistically significant reductions in mean body weight were seen in groups exposed to sulindac. These small reductions in body weight are considered unlikely to have influenced bladder cancer response.
Discussion
The results of the present studies demonstrate that, as a class, NS AIDs are an extremely promising group of agents for bladder cancer chemoprevention. Of the three NSAIDs evaluated in the present studies, sulindac and ketoprofen are among the most potent inhibitors of bladder cancer induction ever evaluated in our laboratory: both reduced the incidence of TCC in OH-BBN-treated mice by >70% in comparison with carcinogentreated dietary controls. In contrast, aspirin conferred no protection against the induction of urinary bladder cancer by OH-BBN. In this regard, the results of the present study in BDF mice are similar to the epidemiology data presented by Thun et al. (25) , who reported that the use of aspirin was not associated with reduced risk of human bladder cancer.
The highly significant suppression of urinary bladder cancer induction achieved by sulindac and ketoprofen contrasts with the results of concurrent studies conducted to evaluate the anti-carcinogenic activity of agents from several other chemical classes. In these studies it was found that dietary administration of the retinoid Ro 16-9100 (300 or 150 p.p.m.) or a combination of vitamin D 3 (2.5 p.p.m.) and calcium glucarate (5000 p.p.m.) conferred only modest protection against bladder cancer induction; these regimens reduced bladder cancer incidence by 40-50% from dietary controls. In contrast, dimethyl fumarate (800 or 400 mg/kg diet), phenethyl isothiocyanate (100 or 50 mg/kg diet) and carbenoxolone (200 or 100 mg/kg diet) conferred no protection against neoplastic development in the OH-BBN/BDF mouse bladder cancer model.
The lack of an inhibitory effect of aspirin in the OH-BBN/ BDF mouse model differs from the results of several previous studies in rats, in which aspirin was effective against the induction of urinary bladder cancer by FANFT (14,15) or OH-BBN (17) . The reasons underlying this apparent species difference are not clear. It should be noted, however, that the bladder neoplasm induced by OH-BBN in the BDF mouse is much more aggressive than is the lesion induced by the same carcinogen in rats (24, 26) . On this basis, although aspirin may confer protection against the relatively slow growing and primarily exophytic lesion induced by OH-BBN in rats, this protection may be overcome by the rapidly growing and highly invasive nature of the lesion induced in the BDF mouse. In addition, interspecies differences in drug disposition, metabolism and pharmacokinetics may contribute to these apparently discordant findings.
Although COX activity is the putative mechanistic target of aspirin and other NSAIDs, the mechanism(s) by which these agents exert their chemopreventive effects in the bladder and other tissues have not been identified conclusively. Activities other than inhibition of COX have been suggested as potentially important in the anti-initiating and anti-promoting effects of several members of this class. In this regard, we have recently reported that the NSAID indomethacin has activity consistent with inhibition of both the COX and lipoxygenase pathways of arachidonic acid metabolism in rat mammary carcinoma cells (27), resulting in decreased production of a wide range of biologically active lipids.
Recent studies on colon carcinogenesis suggest that inducible COX-2 may play an important role in neoplastic development (6, 28) and thus may provide a useful target for the design of cancer chemopreventive drugs. COX products stimulate the proliferation of neoplastic cells in the colon and other tissues and NSAIDs differ in their ability to inhibit COX isozymes. Although their inhibitory activities are quantitatively different, ketoprofen and sulindac act through competitive mechanisms to inhibit both COX isozymes. Aspirin also acts as a competitive COX inhibitor and has unique activity as a non-competitive inhibitor of COX-1 through a covalent binding mechanism (4, 29) . Whether differential inhibitory activity against the two isozymes of COX will generate more active and less toxic chemopreventive agents clearly merits further investigation. It is suggested that specific inhibitors of COX-2 may be less toxic than COX-1 inhibitors for chronic administration protocols and may, therefore, confer a distinct advantage over agents that inhibit both isozymes equally or have predominant activity in the inhibition of COX-1. The relative importance of these two enzymatic pathways as determinants of the anti-carcinogenic activity and toxicological profile of NSAIDs requires further investigation, but may ultimately result in the development of novel agents with improved chemopreventive efficacy.
